Equities analysts predict that Neon Therapeutics Inc (NASDAQ:NTGN) will announce earnings of ($0.63) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Neon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.80). Neon Therapeutics reported earnings of ($0.67) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6%. The business is scheduled to issue its next quarterly earnings results on Monday, November 11th.
According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($2.55) per share for the current year, with EPS estimates ranging from ($3.18) to ($1.85). For the next year, analysts expect that the firm will report earnings of ($2.31) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.01).
Several institutional investors have recently made changes to their positions in NTGN. Marshall Wace North America L.P. bought a new stake in Neon Therapeutics during the 1st quarter valued at $49,000. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after buying an additional 5,000 shares during the last quarter. Rhumbline Advisers bought a new stake in Neon Therapeutics during the 1st quarter valued at $78,000. Bank of New York Mellon Corp raised its holdings in Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after buying an additional 2,905 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares during the last quarter. 69.53% of the stock is owned by institutional investors.
Shares of NASDAQ NTGN traded down $0.01 during midday trading on Monday, hitting $2.39. The company’s stock had a trading volume of 100,700 shares, compared to its average volume of 162,154. The company’s fifty day simple moving average is $3.85. Neon Therapeutics has a one year low of $2.31 and a one year high of $12.69. The company has a quick ratio of 7.30, a current ratio of 6.13 and a debt-to-equity ratio of 0.12. The stock has a market cap of $68.11 million, a price-to-earnings ratio of -0.43 and a beta of 1.62.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
See Also: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.